June 26, 2025

Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2024

  • In line with its commitment to transparency, Grifols has disclosed for the 10th consecutive year all payments and other transfers of value related to medicines and medical technology made to healthcare professionals and healthcare organizations in the several European countries listed within the EFPIA’s (European Federation of Pharmaceutical Industries and Associations) scope, including Spain.
  • In 2024, Grifols made transfers of value in Europe amounting to Euro 17.3 million. This represents a decrease of 19% compared to 2023. Of the total, 61% were transfers of value related to R&D, amounting to Euro 10.6 million.
  • Transfers of value in Spain increased by 15% to Euro 8.1 million, although Spain generated 47% of the group’s total transfers in Europe in 2024 and 64% of those related to R&D.
  • In 2024, Grifols made transfers of value to 249 healthcare professionals in Spain that amounted to Euro 432,628, and to 94 healthcare organizations, which totaled Euro 872,551, excluding those related to R&D in both cases.
  • The EFPIA Code of Practice, which promotes transparency in industry interactions with healthcare professionals, healthcare organizations and patient organizations, applies specifically to medicines. Nonetheless Grifols expands its scope to include transfers unrelated to medications, as well as to all the company’s divisions.
  • In addition to Europe, Grifols applies this policy of transparency to the United States in accordance with CMS (Centers for Medicare & Medicaid Services) Open Payments.
  • All related information is public and available on the Grifols corporate website: www.grifols.com

Information Published in Accordance with the EFPIA Code of Practice

Grifols has voluntarily committed to publishing, on its website and on any specific platform required by each country, information on transfers of value to health professionals and healthcare organizations corresponding to each reporting period. The company will keep this information publicly available for three years and conserve it for six years.

Depending on the type of activity, the published information includes: donations and subsidies; corporate contributions for events, such as membership fees for healthcare professionals and sponsorship agreements with healthcare organizations, as well as payments to third parties designated to manage the event on their behalf; fees paid for consulting services and projects; travel and accommodation expenses incurred in relation to any of the aforementioned activities, and payments and other transfers of value related to R&D activities.

Specifically, the code of conduct is applied in the following European countries: Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom.

Media contacts

Journalist or media professional?

Our media relations team can be reached at:
(+34) 93 571 00 02
media@grifols.com.

Restricted to media inquiries only.

Not a journalist?

For general questions and requests, please contact corporatecomms@grifols.com.